Primecap Management Co. CA Acquires New Shares in Thermo Fisher Scientific Inc. $TMO

Primecap Management Co. CA bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,982,271 shares of the medical research company’s stock, valued at approximately $993,831,000. Primecap Management Co. CA owned about 0.54% of Thermo Fisher Scientific as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Palisade Capital Management LP acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $5,795,000. Canada Pension Plan Investment Board bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $307,944,000. Element Capital Management LLC acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $2,005,000. Legal & General Group Plc bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $1,122,351,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $667,186,000. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Piper Sandler lifted their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Finally, Jefferies Financial Group reissued a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 73,493 shares of company stock worth $43,950,381. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.1%

Thermo Fisher Scientific stock opened at $627.96 on Wednesday. The firm has a market cap of $232.19 billion, a price-to-earnings ratio of 33.78, a PEG ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a 50 day moving average price of $548.75 and a two-hundred day moving average price of $510.05.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period in the prior year, the firm posted $4.28 EPS. The company’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.